NCT01354184已完成2 期
An International, Multi-centre, Randomised, Stratified, Double-blinded, Placebo-controlled, 4-parallel Group Trial Investigating the Efficacy and Safety of Three Different Dose Levels of CRD007 (The AORTA Trial)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 15
研究概览
简要总结
This is an investigation of the efficacy and safety of CRD007 compared to placebo in the treatment of patients with abdominal aortic aneurysm.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Infra-renal abdominal aortic aneurysm
排除标准
- •Previous infra-renal aortic surgery
- •Known diabetes
研究组 & 干预措施
CRD007 matching placebo tablet
Placebo Comparator
干预措施: CRD007 matching placebo (Drug)
CRD007 10 mg tablet
Experimental
干预措施: CRD007 (Drug)
CRD007 25 mg tablet
Experimental
干预措施: CRD007 (Drug)
CRD007 40 mg tablet
Experimental
干预措施: CRD007 (Drug)
研究者
研究点 (15)
Loading locations...
相似试验
已完成
2 期
Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/PhotochemotherapyChronic Plaque PsoriasisNCT00245765UCB Pharma176
已完成
2 期
Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic CardiomyopathyHypertrophic Cardiomyopathy (HCM)NCT04219826Cytokinetics96
终止
2 期
Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic NeuralgiaPainNCT00159640Pfizer315
已完成
2 期
Oral DS107 in Moderate to Severe Atopic DermatitisAtopic DermatitisNCT02211417Dignity Sciences Ltd.102
已完成
2 期
A Study for Patients With Relapsing Remitting Multiple SclerosisRelapsing Remitting Multiple SclerosisNCT00869986Eli Lilly and Company218